logo
Plus   Neg
Share
Email

Merck KGaA Reports Positive Phase IIB Results For Evobrutinib In Relapsing MS

Merck KGaA (MKGAY.PK) announced positive results from its Phase IIb study of evobrutinib (Bruton's Tyrosine Kinase Inhibitor - BTK) in relapsing multiple sclerosis or MS. The study has met its primary endpoint, demonstrating that evobrutinib resulted in a clinically meaningful reduction of gadolinium enhancing T1 lesions measured at weeks 12, 16, 20 and 24 in comparison to patients receiving placebo.

Evobrutinib, discovered by Merck KGaA, Darmstadt, Germany, is also in Phase IIb studies in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alibaba's founder and chairman Jack Ma has said that the Chinese e-commerce giant no longer plans to create 1 million jobs in the US, citing the ongoing trade conflict between the US and China as the reason. "The promise was made on the premise of friendly US-China partnership and rational trade relations,"... California's insurance regulator has filed a lawsuit against AbbVie Inc. for allegedly giving illegal kickbacks to health care providers to prescribe its arthritis drug Humira. The lawsuit filed in Alameda County Superior Court by the California Department of Insurance alleges that private insurers have paid out $1.2 billion in Humira-related pharmacy claims. Danske Bank A/S's Chief Executive Thomas Borgen resigned on Wednesday after the Danish lender announced the results of an internal probe relating to a money-laundering scandal in its branch in Estonia that involved payments of about 200 billion euros. Danske Bank said its investigation covered about 15,000 customers and a total of around 9.5 million payments through the branch.
Follow RTT